Skip to content
Biodatica
Start free

SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany

Nagoya, Aichi-ken

OncologyFiled/Approved
Compare Sign in to watch

What changed

Filed/Approved trial registered: Nirogacestat in Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)

2d agoTrial registeredJul 17, 2026Source filing (opens the source filing in a new tab)

Momentum

90no change

Momentum 90 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Filed/Approved

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

56 pre-ticker oncology companies at Filed/Approved

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE4 registered

    Sep 17, 2025

    Desmoid Tumor, Aggressive Fibromatosis · RECRUITING · sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany · Nirogacestat in Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)

    ClinicalTrials.gov · NCT07176689 (opens the source filing in a new tab)

  2. Trial

    PHASE2 registered

    Aug 8, 2025

    Desmoid Tumor, Aggressive Fibromatosis · ACTIVE_NOT_RECRUITING · sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany · A Study of Nirogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis (DT/AF)

    ClinicalTrials.gov · NCT07170644 (opens the source filing in a new tab)

  3. Trial

    PHASE1 registered

    May 7, 2025

    Healthy, Hepatic Impairment · RECRUITING · sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany · Effect of Hepatic Impairment on the Pharmacokinetics of Mirdametinib

    ClinicalTrials.gov · NCT06997276 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources